Fibroblast Growth Factor Receptor Inhibitors Reduce Adipogenesis of Orbital Fibroblasts and Enhance Myofibroblastic Differentiation in Graves’ Orbitopathy

References

• Smith TJ, Hegedus L. Graves’ disease. N Engl J Med. 2016;375(16):1552–1565. doi:10.1056/NEJMra1510030.
   PubMed Web of Science ®Google Scholar
• Kuriyan AE, Phipps RP, Feldon SE. The eye and thyroid disease. Curr Opin Ophthalmol. 2008;19(6):499–506. doi:10.1097/ICU.0b013e3283131557.
   PubMed Web of Science ®Google Scholar
• Bartalena L, Baldeschi L, Boboridis K, et al. The 2016 European thyroid association/European group on Graves’ orbitopathy guidelines for the management of Graves’ orbitopathy. Eur Thyroid J. 2016;5(1):9–26. doi:10.1159/000443828.
   PubMed Web of Science ®Google Scholar
• Bartalena L. Graves’ orbitopathy: imperfect treatments for a rare disease. Eur Thyroid J. 2013;2(4):259–269. doi:10.1159/000356042.
   PubMedGoogle Scholar
• Garrity JA, Bahn RS. Pathogenesis of graves ophthalmopathy: implications for prediction, prevention, and treatment. Am J Ophthalmol. 2006;142(1):147–153. doi:10.1016/j.ajo.2006.02.047.
   PubMed Web of Science ®Google Scholar
• Smith TJ, Hegedus L, Douglas RS. Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves’ orbitopathy. Best Pract Res Clin Endocrinol Metab. 2012;26(3):291–302. doi:10.1016/j.beem.2011.10.002.
   PubMed Web of Science ®Google Scholar
• Campi I, Vannucchi G, Salvi M. Therapy of endocrine disease: endocrine dilemma: management of Graves’ orbitopathy. Eur J Endocrinol. 2016;175(3):R117–133. doi:10.1530/EJE-15-1164.
   PubMed Web of Science ®Google Scholar
• Chen PY, Qin L, Li G, Tellides G, Simons M. Smooth muscle FGF/TGFbeta cross talk regulates atherosclerosis progression. EMBO Mol Med. 2016;8(7):712–728. doi:10.15252/emmm.201506181.
   PubMed Web of Science ®Google Scholar
• Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discovery. 2009;8(3):235–253. doi:10.1038/nrd2792.
   PubMed Web of Science ®Google Scholar
• Hutley L, Shurety W, Newell F, et al. Fibroblast growth factor 1: a key regulator of human adipogenesis. Diabetes. 2004;53(12):3097–3106. doi:10.2337/diabetes.53.12.3097.
   PubMed Web of Science ®Google Scholar
• Song X, Li Y, Chen X, et al. bFGF promotes adipocyte differentiation in human mesenchymal stem cells derived from embryonic stem cells. Genet Mol Biol. 2014;37:127–134.
   PubMed Web of Science ®Google Scholar
• Matos K, Manso PG, Marback E, Furlanetto R, Alberti GN, Nose V. Protein expression of VEGF, IGF-1 and FGF in retroocular connective tissues and clinical correlation in Graves’ ophthalmopathy. Arq Bras Oftalmol. 2008;71(4):486–492. doi:10.1590/s0004-27492008000400004.
   PubMed Web of Science ®Google Scholar
• Schrijver B, Kooiman MA, Kasteleijn E, et al. Basic fibroblast growth factor induces adipogenesis in orbital fibroblasts: implications for the pathogenesis of Graves’ orbitopathy. Thyroid. 2019. doi:10.1089/thy.2018.0544.
   PubMed Web of Science ®Google Scholar
• SM K, SY L. Effects of PDGF-BB and b-FGF on the production of cytokines, hyaluronic acid and the proliferation of orbital fibroblasts in thyroid ophthalmopathy. Mol Cellular Toxicol. 2013;9:195–202. doi:10.1007/s13273-013-0024-1.
   Web of Science ®Google Scholar
• Virakul S, Heutz JW, Dalm VA, et al. Basic FGF and PDGF-BB synergistically stimulate hyaluronan and IL-6 production by orbital fibroblasts. Mol Cell Endocrinol. 2016;433:94–104. doi:10.1016/j.mce.2016.05.023.
   PubMed Web of Science ®Google Scholar
• Virakul S, van Steensel L, Dalm VA, Paridaens D, van Hagen PM, Dik WA. Platelet-derived growth factor: a key factor in the pathogenesis of graves’ ophthalmopathy and potential target for treatment. Eur Thyroid J. 2014;3(4):217–226. doi:10.1159/000367968.
   PubMedGoogle Scholar
• Ye X, Liu J, Wang Y, Bin L, Wang J. Increased serum VEGF and b-FGF in Graves’ ophthalmopathy. Graefes Arch Clin Exp Ophthalmol. 2014;252(10):1639–1644. doi:10.1007/s00417-014-2662-y.
   PubMed Web of Science ®Google Scholar
• Goetz R, Mohammadi M. Exploring mechanisms of FGF signalling through the lens of structural biology. Nat Rev Mol Cell Biol. 2013;14(3):166–180. doi:10.1038/nrm3528.
   PubMed Web of Science ®Google Scholar
• Carpenter TO, Whyte MP, Imel EA, et al. Burosumab therapy in children with X-linked hypophosphatemia. N Engl J Med. 2018;378(21):1987–1998. doi:10.1056/NEJMoa1714641.
   PubMed Web of Science ®Google Scholar
• Ghedini GC, Ronca R, Presta M, Giacomini A. Future applications of FGF/FGFR inhibitors in cancer. Expert Rev Anticancer Ther. 2018;18(9):861–872. doi:10.1080/14737140.2018.1491795.
   PubMed Web of Science ®Google Scholar
• Midgley AC, Rogers M, Hallett MB, et al. Transforming growth factor-beta1 (TGF-beta1)-stimulated fibroblast to myofibroblast differentiation is mediated by hyaluronan (HA)-facilitated epidermal growth factor receptor (EGFR) and CD44 co-localization in lipid rafts. J Biol Chem. 2013;288(21):14824–14838. doi:10.1074/jbc.M113.451336.
   PubMed Web of Science ®Google Scholar
• Sanders J, Oda Y, Roberts S, et al. The interaction of TSH receptor autoantibodies with 125I-labelled TSH receptor. J Clin Endocrinol Metab. 1999;84(10):3797–3802. doi:10.1210/jcem.84.10.6071.
   PubMed Web of Science ®Google Scholar
• Raju R, Palapetta SM, Sandhya VK, et al. A network map of FGF-1/FGFR signaling system. J Signal Transduct. 2014;2014:962962. doi:10.1155/2014/962962.
   PubMedGoogle Scholar
• Akasaka Y, Ono I, Tominaga A, et al. Basic fibroblast growth factor in an artificial dermis promotes apoptosis and inhibits expression of alpha-smooth muscle actin, leading to reduction of wound contraction. Wound Repair Regener. 2007;15(3):378–389. doi:10.1111/j.1524-475X.2007.00240.x.
   PubMed Web of Science ®Google Scholar
• Itoh N, Ornitz DM. Evolution of the Fgf and Fgfr gene families. Trends Genet. 2004;20(11):563–569. doi:10.1016/j.tig.2004.08.007.
   PubMed Web of Science ®Google Scholar
• Roos JCP, Murthy R. Sirolimus (rapamycin) for the targeted treatment of the fibrotic sequelae of Graves’ orbitopathy. Eye (Lond). 2019;33(4):679–682. doi:10.1038/s41433-019-0340-3.
   PubMed Web of Science ®Google Scholar
• Smith TJ, Kahaly GJ, Ezra DG, et al. Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med. 2017;376(18):1748–1761. doi:10.1056/NEJMoa1614949.
   PubMed Web of Science ®Google Scholar
• Maldiney T, Deschasse C, Bielefeld P. Tocilizumab for the management of corticosteroid-resistant mild to severe Graves’ ophthalmopathy, a report of three cases. Ocul Immunol Inflamm. 2018;1–4. doi:10.1080/09273948.2018.1545914.
   PubMed Web of Science ®Google Scholar
• Du Pasquier-Fediaevsky L, Andrei S, Berche M, Leenhardt L, Heron E, Riviere S. Low-dose rituximab for active moderate-to-severe Graves’ orbitopathy resistant to conventional treatment. Ocul Immunol Inflamm. 2019;27(5):844–850.
   Web of Science ®Google Scholar
• Wang C, Ning Q, Jin K, Xie J, Ye J. Does rituximab improve clinical outcomes of patients with thyroid-associated ophthalmopathy? A systematic review and meta-analysis. BMC Ophthalmol. 2018;18(1):46. doi:10.1186/s12886-018-0679-4.
   PubMedGoogle Scholar
• Widberg CH, Newell FS, Bachmann AW, et al. Fibroblast growth factor receptor 1 is a key regulator of early adipogenic events in human preadipocytes. Am J Physiol Endocrinol Metab. 2009;296(1):E121–131. doi:10.1152/ajpendo.90602.2008.
   PubMed Web of Science ®Google Scholar
• Kuriyan AE, Woeller CF, O’Loughlin CW, Phipps RP, Feldon SE. Orbital fibroblasts from thyroid eye disease patients differ in proliferative and adipogenic responses depending on disease subtype. Invest Ophthalmol Vis Sci. 2013;54(12):7370–7377. doi:10.1167/iovs.13-12741.
   PubMed Web of Science ®Google Scholar